APOD and myeloid sarcoma: It is therefore not unexpected that ApoD overexpression is detected in MS patients (115), and that its presence in MS lesions (116) is low in sclerosis plaques, particularly in inactive ones, but recovers high levels in the re-myelinating lesions when myelin reconstruction is taking place.